(Q40480568)

20 September 2017

title

Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. (English)

1 reference

20 September 2017

0 references

Klaus R Herrlinger

1

1 reference

20 September 2017

Thomas Witthoeft

2

1 reference

20 September 2017

Andreas Raedler

3

1 reference

20 September 2017

Bernd Bokemeyer

4

1 reference

20 September 2017

Thomas Krummenerl

5

1 reference

20 September 2017

Jorg-Dieter Schulzke

6

1 reference

20 September 2017

Norbert Boerner

7

1 reference

20 September 2017

Bruno Kueppers

8

1 reference

20 September 2017

Joerg Emmrich

9

1 reference

20 September 2017

Axel Mescheder

10

1 reference

20 September 2017

Ulrich Schwertschlag

11

1 reference

20 September 2017

Mark Shapiro

12

1 reference

20 September 2017

Eduard F Stange

13

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

The American Journal of Gastroenterology

20 September 2017

published in

1 reference

20 September 2017

volume

101

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

793-797

1 reference

Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00356.X

Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00356.X

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00356.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00356.X

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00356.X

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00356.X

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00356.X

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00356.X

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.00356.X

10.1111/J.1572-0241.2005.00356.X

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference